Search Results - technology+classifications+%3e+therapeutic+modalities

395 Results

Sort By:

Diagnostic and therapeutic target for primary dysautonomia

Value Proposition:· Diagnostic target for broad primary dysautonomia screening.· Broadly applicable therapeutic target for symptom relief in primary and secondary dysautonomia patients.Technology DescriptionResearchers at Johns Hopkins have identified a potential diagnostic and therapeutic target for patients with primary dysautonomia....

Published: 5/3/2024 | Inventor(s): Malcolm Brock, Frank Bosmans

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities > Small Molecules

Treatment of fibrosis-associated pathologies through downstream TGF-β pathway inhibition

Value PropositionInhibits downstream signaling pathway of TGF-β signaling, reducing pleiotropic and off-target effects.Selectively targets tissue specific calpains, increasing efficacy as compared to current TGF-β signaling pathway inhibitory methods.Applicable to several disease models with specific focus on epithelial-to-mesenchymal transition pathologies....

Published: 5/2/2024 | Inventor(s): David Kim, Harry Dietz

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, Fibrosis Disorders, In Vitro Diagnostics, Mechanism-of-action Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Fibrosis, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities

Alkylsulfenyl Thiocarbonates as Precursors to Hydropersulfides

Unmet Need:According to a survey by the CDC, nearly 50% of Americans age 20 and up have some form of cardiovascular disease (see AHA). The management of cardiovascular diseases depends on the specific indication, and standard therapies include one or multiple of the following types of medications: blood thinners, ACE inhibitors, beta-blockers, calcium...

Published: 5/3/2024 | Inventor(s): John Toscano, Vinayak Khodade, Sahil Aggarwal, Nazareno Paolocci, Blaze Pharoah, Gizem Keceli, Kelsey Zhang

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Cardiovascular, Clinical and Disease Specializations > Oncology

Recombinant anti-PAD4 antibodies as a treatment for lung fibrosis

Value PropositionSelective monoclonal antibody therapy to treat lung fibrosis.Directly targets immune cells to promote a pro-inflammatory pathway that reduces fibrosis.High serum levels are associated with less severe lung disease, decreased fibrosis, and improved survival in a subset of rheumatoid arthritis patients.Broadly applicable to other diseases...

Published: 5/3/2024 | Inventor(s): Erika Darrah, Felipe Andrade, Kristen Demoruelle, Elizabeth Redente

Keywords(s):

Category(s): Clinical and Disease Specializations > Fibrosis, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications, Technology Classifications > Therapeutic Modalities

Cell-Permeable Protein Therapeutic for Pain and Itch

Novelty:Identification of a mutant peptide with strong inhibitory effect on nociceptor TRPA1, useful for the prevention and treatment of chronic and acute pain and itch.Value Proposition:Dysregulation of ion channels is associated with various debilitating conditions, including chronic pain and itch. Transient receptor potential ankyrin 1 (TRPA1), an...

Published: 5/2/2024 | Inventor(s): Hao-Jui Weng, Xinzhong Dong

Keywords(s): Biologics, Biomarker, Chronic Pain, CNS and Neurological Disorders, Disease Indication, Mechanism of Action Biomarker, Peptide, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Pain, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Pain > Chronic Pain

Dextran Hydrogel Scaffolds Enhance Angiogenic Responses and Promote Complete Skin Regeneration During Burn Wound Healing

Unmet Need:Third-degree burns involve damage to both the epidermal and dermal layers and may also entail damage to underlying muscles, bones, and tendons. Such burns heal with thick scars, which result in contractures that distort the surrounding tissue. Deep third-degree burns usually require skin grafting to achieve wound closure, but the cosmetic...

Published: 5/2/2024 | Inventor(s): Guoming Sun, Xianjie Zhang, John Harmon, Sharon Gerecht

Keywords(s): Disease Indication, Drug Delivery Vehicle, Hydrogel, Therapeutic Matter, Therapeutics, Wound Healing

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Wound Healing, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

Antitumor drug interrupting glucose metabolism as a therapeutic strategy for cancer

Value Proposition:· Drug reduces tumor burden by interrupting cancer cells’ reliance on glucose metabolism.· Tolerated by healthy, normal cells.· Potential for combination therapy with other modalities (chemotherapy, radiation, immunotherapy, etc.) Technology Description· Researchers at Johns Hopkins have developed a drug to reduce...

Published: 5/3/2024 | Inventor(s): Ling He

Keywords(s):

Category(s): Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

GCPII Inhibition for the Treatment of Sarcopenia and Aging

Unmet Need:Sarcopenia is the progressive loss of muscle mass and function, and is a natural part of the aging process. Age-related muscle loss and weakness can contribute to frailty and increase the likelihood of falls and fractures in older adults. Recent reports found that 5-13% of persons over the age of 65 years and >50% of people 80 years and...

Published: 5/3/2024 | Inventor(s): Barbara Slusher, Carolyn Tallon

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Geriatrics

DOPA and Caffeic Acid Analogs as Novel GCPII Inhibitors

Unmet NeedGlutamate is the primary excitatory neurotransmitter in the human brain [1]. Excessive glutamate signaling can disrupt calcium homeostasis, leading to mitochondrial dysfunction, the overproduction of reactive oxygen species, and neuron loss via necrotic or apoptotic pathways [2]. This phenomenon, known as excitotoxicity, contributes to disease...

Published: 5/3/2024 | Inventor(s): Barbara Slusher, Rana Rais, Takashi Tsukamoto

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Technology Classifications, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules

Nanoparticles for Delivery of Immunoregulatory Materials to T Cells

Value Proposition:· This platform improves current methods for expansion of CD4+ T-cells, which could be used in adoptive transfer therapies.· Improves modulation, activation, and expansion of T cells over current methods used for CAR T-cell therapyTechnology Description· Researchers at Johns Hopkins have developed a nanoparticle-based...

Published: 5/3/2024 | Inventor(s): Jonathan Schneck, Ariel Isser

Keywords(s):

Category(s): Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Oncology, Technology Classifications > Engineering Tech, Technology Classifications > Therapeutic Modalities

1 2 3 4 5 6 7 8 9 10 ...